UBS Oncology Impact Fund L.P., 10% Owner at Harpoon Therapeutics, Inc. (HARP), sold 54,756 shares at $23.67 ($1.2M) on 2021-04-09, disclosed to the SEC on 2021-04-13.
Open-market sale of $1.2M HARP by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.67 | 10,300 | $244K | 20.3% |
| 2 | $23.67 | 10,300 | $244K | 20.3% |
| 3 | $20.72 | 13,528 | $280K | 23.3% |
| 4 | $20.72 | 13,528 | $280K | 23.3% |
| 5 | $21.52 | 6,700 | $144K | 12.0% |
| 6 | $22.68 | 400 |
| $9K |
| 0.8% |
| Total | $21.94 avg | 54,756 | $1.2M | 100% |
| Filing → |
| HOWL | SELL | 2025-10-29 | $685K | — | Filing → |
| ITOS | SELL | 2021-09-27 | $3.2M | — | Filing → |
| CGEM | SELL | 2021-09-02 | $1.3M | — | Filing → |